Cargando…

Monitoring of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor-Sensitizing and Resistance Mutations in the Plasma DNA of Patients With Advanced Non–Small Cell Lung Cancer During Treatment With Erlotinib

BACKGROUND: The feasibility of monitoring epidermal growth factor receptor (EGFR) mutations in plasma DNA from patients with advanced non–small cell lung cancer (NSCLC) during treatment with erlotinib and its relation to disease progression was investigated. METHODS: The amount of EGFR-mutant DNA wa...

Descripción completa

Detalles Bibliográficos
Autores principales: Sorensen, Boe S, Wu, Lin, Wei, Wen, Tsai, Julie, Weber, Britta, Nexo, Ebba, Meldgaard, Peter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BlackWell Publishing Ltd 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4303984/
https://www.ncbi.nlm.nih.gov/pubmed/25103305
http://dx.doi.org/10.1002/cncr.28964
_version_ 1782354013959749632
author Sorensen, Boe S
Wu, Lin
Wei, Wen
Tsai, Julie
Weber, Britta
Nexo, Ebba
Meldgaard, Peter
author_facet Sorensen, Boe S
Wu, Lin
Wei, Wen
Tsai, Julie
Weber, Britta
Nexo, Ebba
Meldgaard, Peter
author_sort Sorensen, Boe S
collection PubMed
description BACKGROUND: The feasibility of monitoring epidermal growth factor receptor (EGFR) mutations in plasma DNA from patients with advanced non–small cell lung cancer (NSCLC) during treatment with erlotinib and its relation to disease progression was investigated. METHODS: The amount of EGFR-mutant DNA was tested in plasma DNA from patients with advanced NSCLC with allele-specific polymerase chain reaction assays. Blood samples from 23 patients with adenocarcinoma of NSCLC that carried tyrosine kinase inhibitor-sensitizing EGFR mutations were taken immediately before treatment with erlotinib. Additional blood samples were taken at timed intervals until erlotinib treatment was withdrawn. RESULTS: The amount of plasma DNA with sensitizing EGFR mutations was found to be reduced after the first cycle of erlotinib treatment in 22 of 23 patients (96%). No patients presented with the resistant T790M mutation in the pretreatment sample, but at the time of disease progression the mutation was detected in plasma from 9 patients (39%). The quantitative data from the current study demonstrated that when a T790M mutation emerged in the blood it was accompanied by an increase in the original sensitizing EGFR mutation. When T790M was detected, it was found to be present in all subsequent blood samples from that patient. Most interestingly, the results of the current study demonstrated that monitoring the EGFR mutations in the blood allows for the detection of the T790M mutation up to 344 days before disease progression is clinically evident (range, 15-344 days). CONCLUSIONS: The results of the current study demonstrated that serial monitoring of EGFR mutations in plasma DNA is feasible and may allow for the early detection of resistance mutations. These results warrant further studies to explore the clinical usefulness of such analysis.
format Online
Article
Text
id pubmed-4303984
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher BlackWell Publishing Ltd
record_format MEDLINE/PubMed
spelling pubmed-43039842015-02-02 Monitoring of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor-Sensitizing and Resistance Mutations in the Plasma DNA of Patients With Advanced Non–Small Cell Lung Cancer During Treatment With Erlotinib Sorensen, Boe S Wu, Lin Wei, Wen Tsai, Julie Weber, Britta Nexo, Ebba Meldgaard, Peter Cancer Original Articles BACKGROUND: The feasibility of monitoring epidermal growth factor receptor (EGFR) mutations in plasma DNA from patients with advanced non–small cell lung cancer (NSCLC) during treatment with erlotinib and its relation to disease progression was investigated. METHODS: The amount of EGFR-mutant DNA was tested in plasma DNA from patients with advanced NSCLC with allele-specific polymerase chain reaction assays. Blood samples from 23 patients with adenocarcinoma of NSCLC that carried tyrosine kinase inhibitor-sensitizing EGFR mutations were taken immediately before treatment with erlotinib. Additional blood samples were taken at timed intervals until erlotinib treatment was withdrawn. RESULTS: The amount of plasma DNA with sensitizing EGFR mutations was found to be reduced after the first cycle of erlotinib treatment in 22 of 23 patients (96%). No patients presented with the resistant T790M mutation in the pretreatment sample, but at the time of disease progression the mutation was detected in plasma from 9 patients (39%). The quantitative data from the current study demonstrated that when a T790M mutation emerged in the blood it was accompanied by an increase in the original sensitizing EGFR mutation. When T790M was detected, it was found to be present in all subsequent blood samples from that patient. Most interestingly, the results of the current study demonstrated that monitoring the EGFR mutations in the blood allows for the detection of the T790M mutation up to 344 days before disease progression is clinically evident (range, 15-344 days). CONCLUSIONS: The results of the current study demonstrated that serial monitoring of EGFR mutations in plasma DNA is feasible and may allow for the early detection of resistance mutations. These results warrant further studies to explore the clinical usefulness of such analysis. BlackWell Publishing Ltd 2014-12-15 2014-08-07 /pmc/articles/PMC4303984/ /pubmed/25103305 http://dx.doi.org/10.1002/cncr.28964 Text en © 2014 The Authors. Cancer published by American Cancer Society. http://creativecommons.org/licenses/by/3.0/ This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Articles
Sorensen, Boe S
Wu, Lin
Wei, Wen
Tsai, Julie
Weber, Britta
Nexo, Ebba
Meldgaard, Peter
Monitoring of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor-Sensitizing and Resistance Mutations in the Plasma DNA of Patients With Advanced Non–Small Cell Lung Cancer During Treatment With Erlotinib
title Monitoring of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor-Sensitizing and Resistance Mutations in the Plasma DNA of Patients With Advanced Non–Small Cell Lung Cancer During Treatment With Erlotinib
title_full Monitoring of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor-Sensitizing and Resistance Mutations in the Plasma DNA of Patients With Advanced Non–Small Cell Lung Cancer During Treatment With Erlotinib
title_fullStr Monitoring of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor-Sensitizing and Resistance Mutations in the Plasma DNA of Patients With Advanced Non–Small Cell Lung Cancer During Treatment With Erlotinib
title_full_unstemmed Monitoring of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor-Sensitizing and Resistance Mutations in the Plasma DNA of Patients With Advanced Non–Small Cell Lung Cancer During Treatment With Erlotinib
title_short Monitoring of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor-Sensitizing and Resistance Mutations in the Plasma DNA of Patients With Advanced Non–Small Cell Lung Cancer During Treatment With Erlotinib
title_sort monitoring of epidermal growth factor receptor tyrosine kinase inhibitor-sensitizing and resistance mutations in the plasma dna of patients with advanced non–small cell lung cancer during treatment with erlotinib
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4303984/
https://www.ncbi.nlm.nih.gov/pubmed/25103305
http://dx.doi.org/10.1002/cncr.28964
work_keys_str_mv AT sorensenboes monitoringofepidermalgrowthfactorreceptortyrosinekinaseinhibitorsensitizingandresistancemutationsintheplasmadnaofpatientswithadvancednonsmallcelllungcancerduringtreatmentwitherlotinib
AT wulin monitoringofepidermalgrowthfactorreceptortyrosinekinaseinhibitorsensitizingandresistancemutationsintheplasmadnaofpatientswithadvancednonsmallcelllungcancerduringtreatmentwitherlotinib
AT weiwen monitoringofepidermalgrowthfactorreceptortyrosinekinaseinhibitorsensitizingandresistancemutationsintheplasmadnaofpatientswithadvancednonsmallcelllungcancerduringtreatmentwitherlotinib
AT tsaijulie monitoringofepidermalgrowthfactorreceptortyrosinekinaseinhibitorsensitizingandresistancemutationsintheplasmadnaofpatientswithadvancednonsmallcelllungcancerduringtreatmentwitherlotinib
AT weberbritta monitoringofepidermalgrowthfactorreceptortyrosinekinaseinhibitorsensitizingandresistancemutationsintheplasmadnaofpatientswithadvancednonsmallcelllungcancerduringtreatmentwitherlotinib
AT nexoebba monitoringofepidermalgrowthfactorreceptortyrosinekinaseinhibitorsensitizingandresistancemutationsintheplasmadnaofpatientswithadvancednonsmallcelllungcancerduringtreatmentwitherlotinib
AT meldgaardpeter monitoringofepidermalgrowthfactorreceptortyrosinekinaseinhibitorsensitizingandresistancemutationsintheplasmadnaofpatientswithadvancednonsmallcelllungcancerduringtreatmentwitherlotinib